A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes

G. Thanabalasingham · N. Shah · M. Vaxillaire · T. Hansen · T. Tuomi ·
D. Gašperiková · M. Szopa · E. Tjora · T. J. James · P. Kokko · F. Loiseleur ·
E. Andersson · S. Gaget · B. Isomaa · N. Nowak · H. Raeder · J. Stanik ·
P. R. Njolstad · M. T. Malecki · I. Klimes · L. Groop · O. Pedersen · P. Froguel ·
M. I. McCarthy · A. L. Gloyn · K. R. Owen

Received: 24 March 2011 / Accepted: 30 June 2011 / Published online: 4 August 2011
© Springer-Verlag 2011

Abstract

Aims/hypothesis An accurate molecular diagnosis of diabetes subtype confers clinical benefits; however, many individuals with monogenic diabetes remain undiagnosed.

Biomarkers could help to prioritise patients for genetic investigation. We recently demonstrated that high-sensitivity C-reactive protein (hsCRP) levels are lower in UK patients with hepatocyte nuclear factor 1 alpha

Electronic supplementary material The online version of this article (doi:10.1007/s00125-011-2261-y) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

G. Thanabalasingham · M. I. McCarthy · A. L. Gloyn ·
K. R. Owen (✉)
Oxford Centre for Diabetes Endocrinology and Metabolism,
University of Oxford, Churchill Hospital,
Headington, Oxford, OX3 7LJ, UK
e-mail: katharine.owen@dr1.ox.ac.uk

G. Thanabalasingham · M. I. McCarthy · A. L. Gloyn ·
K. R. Owen
Oxford NIHR Biomedical Centre, Churchill Hospital,
Oxford, UK

N. Shah · T. J. James
Department of Clinical Biochemistry, John Radcliffe Hospital,
Oxford, UK

M. Vaxillaire · S. Gaget · P. Froguel
CNRS-UMR-8199, University Lille Nord de France,
Lille, France

T. Hansen · E. Andersson · O. Pedersen
Marie Krogh Centre for Metabolic Research,
Section of Metabolic Genetics, Faculty of Health Sciences,
University of Copenhagen,
Copenhagen, Denmark

T. Hansen
Faculty of Health Sciences, University of Southern Denmark,
Odense, Denmark

T. Tuomi · P. Kokko · L. Groop
Department of Medicine, Helsinki University Hospital,
Helsinki, Finland

T. Tuomi · B. Isomaa
Folkhalsan Research Centre, University of Helsinki,
Helsinki, Finland

D. Gašperiková · J. Stanik · I. Klimes
DIABGENE Laboratory, Slovak Academy of Sciences,
Bratislava, Slovakia

M. Szopa · N. Nowak · M. T. Malecki
Department of Metabolic Diseases, Jagiellonian University,
Krakow, Poland

E. Tjora · H. Raeder · P. R. Njolstad
Department of Clinical Medicine, University of Bergen,
Bergen, Norway

E. Tjora · H. Raeder · P. R. Njolstad
Department of Paediatrics, Haukeland University Hospital,
Bergen, Norway

F. Loiseleur
Medical Biology Laboratory, Pasteur Institute, IPL,
Lille, France

(HNF1A)-MODY than in other diabetes subtypes. In this large multi-centre study we aimed to assess the clinical validity of hsCRP as a diagnostic biomarker, examine the genotype–phenotype relationship and compare different hsCRP assays.

Methods High-sensitivity CRP levels were analysed in individuals with HNF1A-MODY ($n=457$), glucokinase (GCK)-MODY ($n=404$), hepatocyte nuclear factor 4 alpha (HNF4A)-MODY ($n=54$) and type 2 diabetes ($n=582$) from seven European centres. Three common assays for hsCRP analysis were evaluated. We excluded 121 participants (8.1%) with hsCRP values >10 mg/l. The discriminative power of hsCRP with respect to diabetes aetiology was assessed by receiver operating characteristic curve-derived C-statistic.

Results In all centres and irrespective of the assay method, meta-analysis confirmed significantly lower hsCRP levels in those with HNF1A-MODY than in those with other aetiologies (z score -21.8 , $p<5\times 10^{-105}$). HNF1A-MODY cases with missense mutations had lower hsCRP levels than those with truncating mutations (0.03 vs 0.08 mg/l, $p<5\times 10^{-5}$). High-sensitivity CRP values between assays were strongly correlated ($r^2\geq 0.91$, $p\leq 1\times 10^{-5}$). Across the seven centres, the C-statistic for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes ranged from 0.79 to 0.97, indicating high discriminative accuracy.

J. Stanik

Children Diabetes Centre at the 1st Department of Paediatrics,
Faculty of Medicine at the Comenius University,
Bratislava, Slovakia

L. Groop

Department of Diabetes and Endocrinology,
Malmö University Hospital,
Malmö, Sweden

O. Pedersen

Hagedorn Research Institute,
Copenhagen, Denmark

O. Pedersen

Faculty of Health Sciences, University of Aarhus,
Aarhus, Denmark

O. Pedersen

Institute of Biomedical Science, Faculty of Health Sciences,
University of Copenhagen,
Copenhagen, Denmark

P. Froguel

Department of Genomics of Common Disease,
School of Public Health, Imperial College London,
London, UK

M. I. McCarthy

Wellcome Trust for Human Genetics, University of Oxford,
Oxford, UK

Conclusions/interpretation In the largest study to date, we have established that hsCRP is a clinically valid biomarker for HNF1A-MODY in European populations. Given the modest costs and wide availability, hsCRP could translate rapidly into clinical practice, considerably improving diagnosis rates in monogenic diabetes.

Keywords Biomarker · High-sensitivity C-reactive protein · hsCRP · Maturity-onset diabetes of the young · MODY

Abbreviations

CRP	C-reactive protein
GCK	Glucokinase
GWAS	Genome-wide association study
HNF1A	Hepatocyte nuclear factor 1 alpha
HNF4A	Hepatocyte nuclear factor 4 alpha
hsCRP	High-sensitivity C-reactive protein
hsCRP M1	hsCRP method 1
hsCRP M2	hsCRP method 2
hsCRP M3	hsCRP method 3
ROC	Receiver operating characteristic

Introduction

Genome-wide association studies (GWAS) have provided a significant breakthrough in understanding the genetic basis of type 2 diabetes, leading to a rapid expansion of the number of confirmed type 2 diabetes risk variants [1]. To date relatively few of these and other recent genomic findings have been translated into clinical applications [1]. However, one promising example of potential translation into clinical practice stems from GWAS reports that common alleles near *HNF1A* are associated with C-reactive protein (CRP) levels at the population level [2, 3]. There was a plausible biological basis for this observation, as the promoter of the *CRP* gene has two binding sites for hepatocyte nuclear factor 1 alpha (HNF1A), HNF1A is required for *CRP* expression and the *Hnf1a*-knockout mouse has reduced *Crp* expression [4–6]. We hypothesised that large-effect, loss-of-function heterozygous *HNF1A* mutations that are causal for MODY might be associated with more substantial CRP reductions, and we recently confirmed this in a UK study [7].

An important question is whether this finding could be the basis of a diagnostic test for HNF1A-MODY. Mutations in *HNF1A* are the commonest form of monogenic diabetes in the UK, with a minimum prevalence estimated at 50–80 per million of the population [8, 9]. There are important clinical implications of establishing an accurate molecular genetic diagnosis of HNF1A-MODY. Low-dose sulfonylureas are the optimal first-line treatment [10] and screening of at-risk family members can be performed. Access to

definitive but expensive diagnostic genetic tests is restricted; furthermore it is challenging to identify MODY patients whose clinical features have significant overlap with both common types of diabetes. Therefore most cases of HNF1A-MODY remain misclassified [8]. The identification of biochemical screening tools (ideally widely available and at low cost) to detect diabetes patients who are most likely to have an underlying *HNF1A* mutation would allow more targeted and efficient use of molecular genetic testing.

In our initial study, high-sensitivity CRP (hsCRP) showed promise as a diagnostic biomarker with a receiver operating characteristic (ROC) curve-derived C-statistic of 0.8 for differentiation of HNF1A-MODY from patients with young adult-onset type 2 diabetes [7]. This is clinically relevant as 3–4% of those with young adult-onset type 2 diabetes in fact have unrecognised HNF1A-MODY [11]. The purpose of this study was to assess the clinical validity of hsCRP as a diagnostic biomarker in larger numbers of individuals and to produce recommendations to guide clinical practice. We also aimed to address limitations of the previous study by: (1) including participants with hepatocyte nuclear factor 4 alpha (HNF4A)-MODY; (2) repeating an hsCRP measurement in individuals who had previously had a raised value; (3) assessing any association between *HNF1A* mutation position and hsCRP level; and (4) comparing several common methods of hsCRP analysis.

Methods

Participants Full details of the recruitment criteria for the participants are described in the electronic supplementary material (ESM) [Methods](#). We studied MODY patients who had a confirmed heterozygous mutation (sequencing performed in a certified diagnostic centre) in *HNF1A* ($n=457$), *GCK* ($n=404$) or *HNF4A* ($n=54$), and were recruited from seven European centres (Table 1). In addition we studied individuals diagnosed at age ≤ 45 years with clinically labelled type 2 diabetes ($n=582$). All MODY mutations

were considered to be pathogenic on the basis of at least one of the following criteria: (1) absence of the variant in normal chromosomes; (2) published reports; (3) presence of a truncating mutation; or (4) co-segregation of the mutation with a MODY phenotype within the family. Of the UK samples, 31 HNF1A-MODY and all glucokinase (GCK)-MODY and young adult-onset type 2 diabetes cases were reported in the previous study [7]. Informed consent was obtained from volunteers in each centre following approval from local ethics committees.

Biochemical methods Due to differences in individual local biochemistry laboratories, CRP was analysed using one of three commonly available high-sensitivity assays. This allowed an assessment of any effect that the specific hsCRP assay used may have had on the derived sensitivity and specificity thresholds to differentiate patients with distinct diabetes aetiologies. This study therefore represents an important evaluation of hsCRP as a screening tool in clinical practice. High-sensitivity CRP method 1 (hsCRP M1), a wide-range latex-enhanced immunoturbidimetric assay on an ADVIA 2400 analyser (Siemens Healthcare Diagnostics, Frimley, UK), was used at a single laboratory at the John Radcliffe Hospital, Oxford, for samples from Denmark, Norway, Poland, Slovakia and the UK. High-sensitivity CRP method 2 (hsCRP M2), a latex-enhanced immunoturbidimetric assay on a Konelab 60i analyser (Thermo Fisher Scientific, Vantaa, Finland), was used for samples from Finland and Sweden. High-sensitivity CRP method 3 (hsCRP M3), an immunonephelometric assay on the BN ProSpec analyser (Siemens Healthcare Diagnostics, Erlangen, Germany), was used to analyse samples from France. The working ranges of the assays were 0.03–160.00 mg/l (hsCRP M1), 0.25–40.00 mg/l (hsCRP M2) and 0.16–10.00 mg/l (hsCRP M3). High-sensitivity CRP values below the lower working ranges of each assay were reported at this lower limit, i.e. 0.03 mg/l (hsCRP M1), 0.25 mg/l (hsCRP M2) and 0.16 mg/l (hsCRP M3). Between-batch estimates of imprecision, expressed as per cent coefficient of variation, were: 10.0% at 0.05 mg/l,

Table 1 Numbers of participants with different diabetes aetiology recruited from seven European centres

Country	HNF1A-MODY	GCK-MODY	HNF4A-MODY	Young adult-onset type 2 diabetes
Denmark	81	11	20	107
Finland/Sweden	112	19	17	42
France	79	215	0	99
Norway	50	30	10	17
Poland	47	17	0	62
Slovakia	46	88	2	0
UK	42	24	5	255
Total	457	404	54	582

6.7% at 0.48 mg/l and <1% at 23.5 mg/l (hsCRP M1); <10% at >0.8 mg/l (hsCRP M2); and 3.1% at 0.5 mg/l and 3.4% at 2.1 mg/l (hsCRP M3).

Calculations In line with previous studies, hsCRP values >10 mg/l were considered likely to represent an acute inflammatory response and were excluded from further analyses [7, 12, 13]. From 1,497 samples, 121 (8.1%) were removed as follows: seven (1.5%) HNF1A-MODY; eight (2.0%) GCK-MODY; three (5.5%) HNF4A-MODY; and 103 (17.7%) type 2 diabetes.

Statistical methods Values of hsCRP from Denmark, Norway, Poland, Slovakia and the UK were combined, as these samples were all analysed in a single laboratory in Oxford, whereas data from France and Finland/Sweden are reported separately. Skewed data including hsCRP values are reported as medians and interquartile ranges. Non-parametric tests (Mann–Whitney, Kruskal–Wallis) were used to compare hsCRP values between groups. Data from all centres were combined in a fixed effects meta-regression (Hedges–Olkin approach) using the statistical package Comprehensive Meta-Analysis (www.meta-analysis.com). All other statistical analysis was performed in SPSS (version 17; SPSS, Chicago, IL, USA). Pearson's correlation coefficient was used to assess correlations between continuous variables. The performance of hsCRP as a diagnostic test for HNF1A-MODY was evaluated using ROC curve analysis. A summary ROC curve was constructed to combine all hsCRP values using the sensitivities and specificities from each centre [14]. A value of $p < 0.05$ was considered to be significant.

Genotype–phenotype relationship Age of diagnosis of diabetes is altered by the type and location of *HNF1A* mutations. In one study lower age of diabetes diagnosis has been shown to be associated with missense mutations in exons expressed in all three isomers HNF1A(A), (B) and (C) [15]. In another study, lower age of diabetes diagnosis was associated with missense mutations within the dimerisation and DNA-binding domains [16]. Therefore we tested the effect on hsCRP levels of: (1) the isomer of HNF1A affected; (2) the functional domain of HNF1A affected; and (3) the type of *HNF1A* mutation. *HNF1A* mutations were grouped as: exons 1–6 [affects isomers HNF1A(A), (B) and (C)]; exon 7 [isomers HNF1A(A), and (B)]; and exons 8–10 [isomer HNF1A(A) only]. Mutations were also grouped according to the functional domain affected (dimerisation, DNA-binding or transactivation). Mutations were classified as either missense mutations resulting in amino acid changes or those predicted to generate a premature stop codon, i.e. truncating mutations. The latter group includes nonsense, frameshift and splicing

mutations. To account for non-independence, these analyses were restricted to a single individual from each family.

Comparison of hsCRP assays A preliminary assessment of hsCRP assay comparability was undertaken at the John Radcliffe Hospital, Oxford, and assessed using the Passing–Bablok regression method [17]. Using hsCRP M1, we re-analysed 26 samples from Sweden/Finland (originally analysed using hsCRP M2) and 30 samples from France (originally analysed using hsCRP M3).

Repeat of previously elevated CRP results In our previous report, 90 (11%) cases (including three with HNF1A-MODY) who had hsCRP >10 mg/l were excluded. We repeated the hsCRP measurement in 22 of these individuals. Repeat testing was not possible on those with elevated hsCRP values from the other European centres.

Results

High-sensitivity CRP results Results of hsCRP analysis are summarised in Fig. 1 and detailed in Table 2. In each centre and irrespective of the assay used, hsCRP levels were significantly lower in individuals with HNF1A-MODY than in those with other diabetes aetiologies. The hsCRP levels associated with the respective diabetes subtypes

Fig. 1 Interquartile ranges of hsCRP (mg/l) by diabetes aetiology using three analytical assays for samples from Denmark, Norway, Poland, Slovakia and the UK (hsCRP M1), Finland and Sweden (hsCRP M2), and France (hsCRP M3). Values of hsCRP >10 mg/l were excluded. Kruskal–Wallis tests were used to calculate p values between groups; $*p = 3.3 \times 10^{-72}$, $**p = 4.7 \times 10^{-9}$ and $***p = 5.3 \times 10^{-18}$. Continuous black bars, HNF1A-MODY; dashed bars, GCK-MODY; dotted bars, HNF4A-MODY; continuous grey bars, type 2 diabetes

Table 2 HsCRP results

Diabetes subtype by country of origin ^a	hsCRP (mg/l) (includes all values)	hsCRP (mg/l) (excludes values >10 mg/L)	<i>p</i> value ^b	<i>p</i> value ^c
UK				
HNF1A-MODY	0.17 (0.05–0.98)	0.14 (0.13–0.39)	5.2×10 ^{−9}	1.4×10 ^{−10}
GCK-MODY	1.25 (0.43–3.53)	1.25 (0.43–3.53)		
HNF4A-MODY	1.17 (0.18–5.30)	1.17 (0.18–5.30)		
Type 2 diabetes	3.25 (0.71–9.49)	1.78 (0.52–4.73)		
Denmark				
HNF1A-MODY	0.03 (0.03–0.08)	0.03 (0.03–0.08)	1.8×10 ^{−26}	1.7×10 ^{−26}
GCK-MODY	0.71 (0.03–3.96)	0.22 (0.03–0.80)		
HNF4A-MODY	1.42 (0.34–2.10)	1.42 (0.34–2.10)		
Type 2 diabetes	3.33 (1.00–6.93)	2.07 (0.88–4.49)		
Norway				
HNF1A-MODY	0.05 (0.03–0.14)	0.05 (0.03–0.14)	1.7×10 ^{−7}	1.3×10 ^{−5}
GCK-MODY	0.60 (0.14–3.08)	0.55 (0.14–2.78)		
HNF4A-MODY	2.20 (10.2–3.96)	2.03 (1.02–3.04)		
Type 2 diabetes	5.21 (2.26–16.30)	3.65 (0.32–5.21)		
Poland				
HNF1A-MODY	0.03 (0.03–0.12)	0.03 (0.03–0.09)	4.6×10 ^{−10}	2.1×10 ^{−10}
GCK-MODY	0.29 (0.09–0.65)	0.29 (0.09–0.65)		
Type 2 diabetes	1.98 (0.79–4.58)	1.56 (0.22–2.79)		
Slovakia				
HNF1A-MODY	0.03 (0.03–0.11)	0.03 (0.03–0.11)	8.9×10 ^{−5}	N/A
GCK-MODY	0.17 (0.04–0.72)	0.17 (0.04–0.71)		
HNF4A-MODY	4.75 (0.13–9.36)	4.75 (0.13–9.36)		
Finland/Sweden				
HNF1A-MODY	0.25 (0.25–0.54)	0.25 (0.25–0.54)	4.7×10 ^{−9}	1.2×10 ^{−8}
GCK-MODY	0.69 (0.25–2.11)	0.69 (0.25–2.11)		
HNF4A-MODY	0.99 (0.49–1.63)	0.99 (0.49–1.63)		
Type 2 diabetes	1.44 (0.40–3.92)	1.44 (0.40–3.92)		
France				
HNF1A-MODY	0.16 (0.16–0.49)	0.16 (0.16–0.49)	5.3×10 ^{−18}	2.0×10 ^{−15}
GCK-MODY	0.62 (0.28–1.28)	0.62 (0.28–1.18)		
Type 2 diabetes	1.60 (0.70–5.09)	1.44 (0.68–4.48)		

All hsCRP are reported as median (25th to 75th centiles), HsCRP ≤ 10 mg/l unless stated otherwise

^a Assays as follows: hsCRP M1 UK, Denmark, Norway, Poland and Slovakia; hsCRP M2 Sweden and Finland, hsCRP M3 France

^b Across all groups, by Kruskal–Wallis test

^c HNF1A-MODY vs type 2 diabetes, by Mann–Whitney test

N/A, not available

varied between centres. This partly reflects the specific hsCRP assay used (for example the median values of the HNF1A-MODY cases cluster at or near the assay's lower reporting limit). Meta-analysis, excluding the previously reported UK samples, confirmed that hsCRP levels were lower in HNF1A-MODY than in other diabetes subtypes across the other six centres (*z* value -20.5 , $p < 5 \times 10^{-93}$) [7]. Meta-analysis across all samples concurred with this result (*z* value -21.8 , $p < 5 \times 10^{-105}$).

Clinical characteristics and hsCRP levels The clinical characteristics of the participants are shown in ESM Table 1. Clinical variables significantly differed between the aetiological groups in line with previous studies [18]. Fasting plasma glucose ($r^2=0.04$), age of diabetes diagnosis ($r^2=0.08$) and BMI ($r^2=0.23$) were significantly correlated with hsCRP levels ($p < 0.05$). Adjustment for these variables did not affect the magnitude or significance of hsCRP differences observed between the groups; this is impor-

tant, as any adjustment of the hsCRP value for use as a screening biomarker would be impractical. The effect of statin and/or aspirin therapy on hsCRP levels was examined. In HNF1A-MODY, HNF4A-MODY and young adult-onset type 2 diabetes cases the hsCRP levels were similar between statin and/or aspirin users and non-users ($p>0.05$). In comparison, participants with GCK-MODY taking statins and/or aspirin had higher hsCRP levels than non-users (1.78 vs 1.22 mg/l, $p=0.03$). Thus, as reported previously, it seems unlikely that the use of these drugs in patients with other forms of diabetes would lower hsCRP towards the levels seen in HNF1A-MODY patients [7].

High-sensitivity CRP is a clinically valid biomarker for HNF1A-MODY The differences in hsCRP values between HNF1A-MODY patients and other diabetes subtypes are statistically convincing, but this does not necessarily translate into a clinically valid biomarker. The ROC curve-derived C-statistic (measures discriminative accuracy) was calculated for unadjusted hsCRP levels. The C-statistic to distinguish HNF1A-MODY from other diabetes subtypes ranged from 0.72 to 0.95 across the centres and from 0.76 to 0.86 across the three hsCRP assays (Table 3). The C-statistic for HNF1A-MODY vs young adult-onset type 2 diabetes ranged from 0.79 to 0.97 across the centres and from 0.79 to 0.91 across the three hsCRP assays (Table 3, Fig. 2a). This indicates that hsCRP can reliably distinguish HNF1A-MODY from young adult-onset type 2 diabetes across European populations, even when different hsCRP assays are used. The hsCRP M2 and hsCRP M3 assays have lower discriminative accuracy, which is likely to reflect their less precise lower detection limits (0.25 and 0.16 mg/l, respectively, compared with 0.03 mg/l for hsCRP M1).

In samples from Denmark, Norway, Poland, Slovakia and the UK, a diagnostic threshold of 0.25 mg/l conferred

83% sensitivity and 86% specificity for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes. This is revised to 81% sensitivity and 88% specificity if hsCRP values >10 mg/l are not excluded. Different hsCRP assays, i.e. those used to analyse the French and Finnish/Swedish samples, were associated with different thresholds for optimum sensitivity and specificity; thus a cut-off of 0.5 mg/l conferred 76% sensitivity and 81% specificity in French samples and 74% sensitivity and 68% specificity in Finnish/Swedish samples for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes. It is likely that the higher hsCRP cut-off in the French and Finnish/Swedish samples reflects the different reporting ranges of the hsCRP assays used to assess these samples. The summary ROC curve, which was based on combining all unadjusted hsCRP values ≤ 10 mg/l irrespective of the assay used, indicated high sensitivity (78%) and specificity (80%) for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes (Fig. 2b).

It is likely that a biomarker such as hsCRP would be most effective as a screening tool for HNF1A-MODY when used in conjunction with clinical features. In our previous report, the proposed strategy for selection of young adult-onset type 2 diabetes cases for genetic testing was either hsCRP ≤ 0.2 mg/l or fulfilment of traditional criteria for MODY testing (i.e. age of diabetes diagnosis ≤ 25 years plus two consecutive generations of diabetes) [7]. This resulted in $\sim 80\%$ sensitivity and specificity. In the current dataset, use of combined criteria, i.e. hsCRP ≤ 0.25 mg/l (hsCRP M1) or hsCRP ≤ 0.5 mg/l (hsCRP M2/ M3) or age of diagnosis ≤ 25 years, resulted in improved sensitivity for detection of HNF1A-MODY ($\sim 90\%$) without much loss in specificity compared with the sensitivity and specificity quoted above (ranged from 65% to 81% across assays).

We evaluated hsCRP as a biomarker to differentiate between MODY subtypes. The levels of hsCRP were

Table 3 ROC curve-derived C-statistic (95% CI) for discrimination between different diabetes aetiologies

Country of origin ^a	C-statistic HNF1A-MODY (95% CI)			
	Versus all	Versus type 2 diabetes	Versus GCK-MODY	Versus HNF4A-MODY
UK	0.82 (0.75, 0.89)	0.83 (0.76, 0.90)	0.79 (0.68, 0.91)	0.77 (0.55, 0.98)
Denmark	0.95 (0.91, 0.98)	0.97 (0.96, 0.99)	0.72 (0.50, 0.93)	0.93 (0.85, 1.0)
Norway	0.82 (0.73, 0.90)	0.91 (0.83, 0.99)	0.76 (0.64, 0.88)	0.89 (0.77, 1.00)
Poland	0.84 (0.76, 0.93)	0.87 (0.79, 0.95)	0.75 (0.61, 0.89)	N/A
Slovakia	0.72 (0.63, 0.81)	N/A	0.71 (0.62, 0.80)	N/A
Finland/Sweden	0.76 (0.69, 0.84)	0.79 (0.69, 0.88)	0.70 (0.55, 0.84)	0.78 (0.66, 0.90)
France	0.76 (0.70, 0.83)	0.85 (0.79, 0.91)	0.73 (0.65, 0.80)	N/A
hsCRP M1 (all)	0.86 (0.83, 0.88)	0.91 (0.89, 0.94)	0.73 (0.68, 0.78)	0.89 (0.83, 0.94)

^a Assays as follows: UK, Denmark, Norway, Poland and Slovakia hsCRP M1; Sweden and Finland hsCRP M2; France hsCRP M3

N/A, not available

Fig. 2 **a** ROC curves illustrate the performance of hsCRP in discriminating between HNF1A-MODY and type 2 diabetes patients across European centres (hsCRP values >10 mg/l excluded). Samples were from: Denmark (black line) (AUC 0.97); Norway (red line) (AUC 0.91); Poland (green line) (AUC 0.87); UK (yellow line) (AUC 0.83); Finland (blue line) (AUC 0.79); and France (purple line) (AUC 0.85). **b** Summary ROC curve combining all samples (hsCRP values >10 mg/l excluded). Samples were analysed by assay as follows: hsCRP M1 (circle); hsCRP M2 (square); and hsCRP M3 (triangle). The continuous line is the line of best fit

significantly different between HNF1A-MODY and HNF4A-MODY cases, and between HNF1A-MODY and GCK-MODY cases ($p < 5 \times 10^{-4}$ and $p < 0.005$, respectively, for all pairwise comparisons across assays). The C-statistic for HNF1A-MODY vs HNF4A-MODY cases ranged from 0.77 to 0.93 across centres, indicating that hsCRP can discriminate well between these MODY subtypes. The C-statistic for HNF1A-MODY vs GCK-MODY cases ranged from 0.70 to 0.79, indicating that hsCRP confers less good discrimination between these MODY subtypes.

Genotype–phenotype relationship Analyses excluded samples measured with hsCRP M2 and M3 due to the insufficiently precise hsCRP values for the majority of HNF1A-

Fig. 3 **a** Bland–Altman plot showing percentage difference in hsCRP results (mg/l) as measured by hsCRP M1 vs hsCRP M2 assays, and by **(b)** hsCRP M1 vs hsCRP M3 assays. Horizontal bars represent the mean bias with 95% limits of agreement shown by the vertical error bars

MODY individuals tested with these assays. ESM Table 2 shows the median hsCRP values reported according to mutation position. Analysis of mutation position by functional domain indicated that the hsCRP levels associated with mutations affecting the dimerisation/DNA-binding domains were significantly lower than those affecting the trans-activation domain (0.03 vs 0.10 mg/l, $p = 4.4 \times 10^{-6}$). The effect of functional domain on hsCRP level was restricted to missense mutations only (0.03 vs 0.16 mg/l, $p = 0.001$), with no significant correlation noted for truncating mutations ($p = 0.83$). Analysis by mutation type showed median hsCRP was lower in HNF1A-MODY cases with missense mutations than in those with truncating mutations (0.03 vs 0.08, $p = 1.5 \times 10^{-5}$). The isomer affected had no effect on hsCRP ($p = 0.25$).

High-sensitivity CRP assay comparison The comparison of hsCRP assays showed good agreement between hsCRP M1 and hsCRP M2 ($r^2 = 0.91$, $p < 9 \times 10^{-5}$), with no significant difference between values obtained from the two assays ($p = 0.20$) (Fig. 3a). Although there was good correlation between hsCRP M1 and hsCRP M3 ($r^2 = 0.99$, $p < 8 \times 10^{-26}$), there were significant differences between the values obtained via these two assays ($p = 0.001$). Passing–Bablok analysis indicated a constant bias (intercept 0.32, 95% CI 0.03, 0.15) combined with proportional bias (slope 0.70, 95% CI 0.68, 0.75) between hsCRP M1 and hsCRP M3 (ESM Fig. 1). This means that the hsCRP values derived from hsCRP M1 were

generally higher, except for values below 1 mg/l where hsCRP M3 generated markedly higher values (Fig. 3b).

Repeat of previously elevated CRP results Of the participants who had hsCRP >10 mg/l in the previous study, three HNF1A-MODY patients and 19 of the 42 with young adult-onset type 2 diabetes agreed to a repeat test after a minimum interval of 1 week [7]. ESM Fig. 2 shows the initial and repeat hsCRP results. One HNF1A-MODY patient and ten of 19 young adult-onset type 2 diabetes patients had persistently elevated hsCRP >10 mg/l. The repeat hsCRP values in two of the HNF1A-MODY patients remained well above the proposed threshold of 0.25 mg/l, and therefore these individuals would not have been offered genetic testing on the basis of hsCRP alone. Interestingly, only seven of 457 (1.5%) HNF1A-MODY patients in the current study had an hsCRP value >10 mg/l, which suggests that very few MODY cases would be missed even if those with initially high hsCRP values were not re-tested.

Discussion

In this study we confirm that individuals with HNF1A-MODY have significantly lower levels of hsCRP than individuals with young adult-onset type 2 diabetes and other MODY subtypes. This dataset represents the largest reported collection of MODY participants and includes individuals recruited from across Europe. As a screening biomarker used in isolation, hsCRP performed well across all centres in identifying participants with *HNF1A* mutations; the ROC-derived C-statistic for distinguishing HNF1A-MODY patients from those with young adult-onset type 2 diabetes ranged from 0.79 to 0.91. Performance was improved when an assay-specific hsCRP cut-off was combined with age of diabetes diagnosis, with the combined criteria achieving sensitivities of ~90% and specificities of up to 81%. This study establishes that hsCRP is by far the most robust clinical biomarker identified to date for the diagnosis of diabetes subtypes.

We extended the diabetes subtypes examined to show for the first time that lower hsCRP levels are not observed in HNF4A-MODY patients. This was not unexpected as there is no evidence that *CRP* expression is regulated directly by HNF4A. Interestingly, a recent GWAS reported that common alleles near *HNF4A* were associated with CRP levels in healthy individuals; the small effect seen might be mediated indirectly via the regulation of *HNF1A* by HNF4A [19]. It is a challenging task to discriminate between patients with HNF1A-MODY and those with HNF4A-MODY by clinical presentation alone [20]. Therefore patients whose clinical features are suggestive of transcription factor-MODY undergo resequencing of

HNF1A and *HNF4A*, with *HNF1A* being sequenced first as these mutations are more common. In this dataset, hsCRP discriminated well between HNF1A-MODY and HNF4A-MODY patients, and we suggest that, along with birthweight, hsCRP could be used to guide molecular genetic investigation in patients with features of transcription factor-MODY [21].

The current study only addresses the discrimination between HNF1A-MODY and type 2 diabetes in young adults. High-sensitivity CRP did not distinguish as effectively between HNF1A-MODY and GCK-MODY patients; indeed, other biochemical features can better differentiate these MODY subtypes [22, 23]. We did not assess hsCRP as a diagnostic biomarker in children with diabetes, where the differential diagnosis is from type 1 diabetes. In our previous study, hsCRP did not discriminate reliably between these two aetiological subtypes in adults [7]; moreover, the lower hsCRP noted in children [24, 25] would be likely to diminish the difference further. This should be evaluated in children, but we suspect that other biomarkers (in addition to autoantibodies and C-peptide) will need to be developed to distinguish recently diagnosed type 1 diabetes from MODY.

We have shown some evidence for a genotype–phenotype relationship within HNF1A-MODY cases, as missense mutations affecting the dimerisation and DNA-binding domains have significantly lower hsCRP levels than mutations disrupting the transactivation domain. These results suggest that the functional outcome of missense mutations affecting binding to the DNA consensus sequence is more severe than that of those affecting the transactivation domain. The lower hsCRP levels observed are consistent with the previous study reporting decreased age of diabetes diagnosis in patients with missense mutations within the DNA-binding/dimerisation domain compared with those in the transactivation domain [16]. Importantly the sensitivity and specificity of hsCRP as a biomarker was not affected by the type or position of the underlying *HNF1A* mutation.

In our previous and current studies we excluded individuals with hsCRP values >10 mg/l from analysis. The persistently raised hsCRP levels in ten of 19 individuals with clinically labelled young adult-onset type 2 diabetes are likely to reflect the low-grade inflammation associated with insulin resistance [26, 27]. Two HNF1A-MODY patients had atypical MODY phenotypes complicated by insulin resistance and the metabolic syndrome, and this may explain their persistently raised hsCRP values [28]. *HNF1A* mutation carriers with mixed phenotypes that include insulin resistance will probably not be identified using hsCRP. To reduce the possibility of an acute elevation of CRP due to an intercurrent infection, we recommend repeating the test after a few weeks in any individual whose

clinical presentation is consistent with HNF1A-MODY, but who has elevated hsCRP. HNF1A-MODY should not be excluded on the basis of an elevated hsCRP in patients under high clinical suspicion.

Currently available hsCRP assays have been optimised at concentrations higher than those observed in the present study. The comparison of three analytical assays demonstrated significant variation and bias within the normal hsCRP range. Importantly, all assays tested could discriminate between those with HNF1A-MODY and those with other diabetes subtypes. However, it is clear that the specific hsCRP assay used influences the optimal threshold for selecting an individual for *HNF1A* sequencing. The hsCRP M1 assay used in Oxford reports to a much lower minimum hsCRP value (0.03 mg/l) than the hsCRP M2 (0.25 mg/l) and hsCRP M3 (0.16 mg/l) assays. Therefore the majority of French and Finnish/Swedish HNF1A-MODY cases had hsCRP levels below the range of the specific assay and the median hsCRP for HNF1A-MODY cases was at the lower limit of each analytical assay. Furthermore, the absolute hsCRP difference between HNF1A-MODY individuals and those with other diabetes subtypes reported using assays hsCRP M2 and M3 is likely to be underestimated. This may account for the lower discriminative power (or C-statistic) when using these analytical assays. Optimum sensitivity and specificity values for diagnostic testing were found at a higher hsCRP level in these samples than in those analysed with hsCRP M1 (0.5 vs 0.25 mg/l). It is clear that the use of an hsCRP assay with a low reporting range provides enhanced discrimination between diabetes subtypes. We therefore recommend an assay with a similar reporting range to hsCRP M1 for use in diabetes diagnostics. Due to inter-method and inter-laboratory variability, each MODY diagnostic testing centre will need to establish the threshold for sequencing based on a specific local hsCRP assay.

Future studies to confirm the clinical utility of this biomarker will require prospective use of hsCRP to identify cases for sequencing of *HNF1A* from unselected groups of individuals with young adult-onset diabetes. Accompanying health economic analysis will also be necessary to demonstrate the cost-effectiveness of a screening pathway involving hsCRP, and to establish the optimum sensitivity and specificity cut-offs for diagnostic screening.

In summary, this study establishes that hsCRP is a clinically valid biomarker for diagnosis of HNF1A-MODY. We propose that hsCRP be incorporated into diagnostic algorithms in conjunction with other clinical and biochemical features to select individuals with diabetes for resequencing of *HNF1A*. An advantage of hsCRP as a screening biomarker is that it is already widely available at relatively low cost (~€5.00 per test) and therefore has great potential to be rapidly adopted in clinical practice. High-

sensitivity CRP has sufficient sensitivity and specificity to facilitate more precise targeting of molecular diagnostic testing for monogenic diabetes, and therefore should improve detection of HNF1A-MODY individuals and lead to better care for these patients. Furthermore molecular genetic diagnostics is likely to become more widespread following the impact of next-generation sequencing techniques, and biomarkers such as hsCRP may become reliable tools to assist the clinical interpretation of novel mutations of uncertain pathogenic significance.

Acknowledgements We thank the patients and families for taking part in this study. We also thank M. Huckova and L. Valentinova for their help with the DNA analysis (Slovakian samples). K.R. Owen is an NIHR-funded Clinician Scientist. A.L. Gloyn is a Medical Research Council (MRC) New Investigator (81696). E. Tjora, H. Raeder and P.R. Njolstad were funded by the University of Bergen, Helse Vest, Innovest and the Research Council of Norway. D. Gašperiková, J. Stanik and I. Klimes acknowledge grant support from BITCET and VEGA 2/0151/11. The study was funded by the Oxford (NIHR) Biomedical Research Centre, Diabetes UK and the European Community FP7 programmes CEED3 (HEALTH-F2-2008-223211) and ENGAGE (HEALTH-F4-2007-201413). The Danish part of the study was supported by grants from the Lundbeck Foundation Centre for Applied Medical Genomics in Personalized Disease Prediction, Prevention and Care (LuCAMP), the Danish Diabetes Association and the Danish Research Council. The Marie Krogh Centre for Metabolic Research is funded by the Novo Nordisk Foundation.

Contribution statement All authors contributed to interpretation of data, revision of the article for important intellectual content and final approval of the version to be published. In addition, GT, MIM, ALG and KRO contributed to study conception and design, analysis of data and drafting of the article.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

References

- McCarthy MI (2010) Genomics, type 2 diabetes, and obesity. *N Engl J Med* 363:2339–2350
- Reiner AP, Barber MJ, Guan Y et al (2008) Polymorphisms of the *HNF1A* gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. *Am J Hum Genet* 82:1193–1201
- Ridker PM, Pare G, Parker A et al (2008) Loci related to metabolic-syndrome pathways including *LEPR*, *HNF1A*, *IL6R*, and *GCKR* associate with plasma C-reactive protein: the Women's Genome Health Study. *Am J Hum Genet* 82:1185–1192
- Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G (1990) Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. *EMBO J* 9:4467–4475
- Nishikawa T, Hagihara K, Serada S et al (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. *J Immunol* 180:3492–3501
- Shih DQ, Bussen M, Sehaye E et al (2001) Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. *Nat Genet* 27:375–382

7. Owen KR, Thanabalasingham G, James TJ et al (2010) Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to *HNF1A* mutations. *Diabetes Care* 33:1919–1924
8. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? *Diabetologia* 53:2465–2467
9. Kropff J, Selwood MP, McCarthy MI, Farmer AJ, Owen KR (2011) Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. *Diabetologia* 54:1261–1263
10. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. *Lancet* 362:1275–1281
11. Thanabalasingham G, Pal A, Farmer AJ, Ellard S, McCarthy MI, Owen KR (2010) Extending criteria for genetic testing increases diagnosis of maturity-onset diabetes of the young. *Diabetologia* 53:S63 (abstract 137)
12. Lee CC, Adler AI, Sandhu MS et al (2009) Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. *Diabetologia* 52:1040–1047
13. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation* 107:363–369
14. Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 12:1293–1316
15. Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT (2006) Isomers of the *TCF1* gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. *Hum Mol Genet* 15:2216–2224
16. Bellanne-Chantelot C, Carette C, Riveline JP et al (2008) The type and the position of *HNF1A* mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. *Diabetes* 57:503–508
17. Passing H, Bablok W (1983) A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. *J Clin Chem Clin Biochem* 21:709–720
18. Murphy R, Ellard S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. *Nat Clin Pract Endocrinol Metabol* 4:200–213
19. Dehghan A, Dupuis J, Barbalic M et al (2011) Meta-analysis of genome-wide association studies in >80,000 subjects identifies multiple loci for C-reactive protein levels. *Circulation* 123:731–738
20. Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. *Diabetologia* 51:546–553
21. Pearson ER, Boj SF, Steele AM et al (2007) Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the *HNF4A* gene. *PLoS Med* 4:e118
22. Stride A, Vaxillaire M, Tuomi T et al (2002) The genetic abnormality in the beta cell determines the response to an oral glucose load. *Diabetologia* 45:427–435
23. Pal A, Farmer AJ, Dudley C et al (2009) Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. *Diabetes Care* 33:252–257
24. Whincup PH, Nightingale CM, Owen CG et al (2010) Early emergence of ethnic differences in type 2 diabetes precursors in the UK: the Child Heart and Health Study in England (CHASE Study). *PLoS Med* 7:e1000263
25. Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM (2003) C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. *Clin Chem* 49:1353–1357
26. Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* 51:1596–1600
27. Tabak AG, Kivimaki M, Brunner EJ et al (2010) Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. *Eur J Endocrinol* 163:89–95
28. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 23:469–480